Medivizor Takes on WebMD, Dr. Google, With Customized Health Service

8/21/13Follow @benthefidler

(Page 2 of 2)

open up an account specifying what condition he or she was suffering from and some demographic details, but without revealing any of their private information. Medivizor would ask a series of questions (between 5 and 15) about the disease—for example, what type of treatment the person has already received, what types are being considered—to pinpoint the exact nature of the patient’s condition.

Medivizor would then provide an initial report tailored to the subscriber with items such as treatment options given the person’s specific situation. After that, the company would send the subscriber a customized information alert whenever relevant new information became available—about a new clinical trial or data published in a medical journal, say. Those alerts would be written by an in-house team that translated medical jargon into something a 10th grade English student could understand, Givoly says.

As a person’s condition changed, he or she could update the profile, and receive updates tweaked to account for them.

“It gives people the peace of mind that they could better manage their condition,” Givoly says.

Despite the number of companies coming up with new ways to utilize personal health information, Givoly asserts that Medivizor is providing the only service of its kind. WebMD, for example, inked a partnership with Qualcomm Life in March geared towards tailoring health information to consumers by linking data from their health devices—like a glucose meter—to a WebMD app. But Givoly says that that initiative is focusing on pieces of data, rather than the whole picture of a person’s health condition.

“We really capture the essence of what makes one person different from another, not the granular data that needs to be mined for information,” he says. “It’s the whole situation—not one aspect that could be monitored with a FitBit.”

That’s all well and good, but how to turn the idea into a profitable business? Givoly says the company has three plans to do so. One is charging a fee for referrals that Medivizor would make to connect a patient to a “hard to match” clinical trial, or to certain medical services or second opinions, Givoly says.

Another avenue would be licensing the service to hospitals and clinics. And a third option would be starting a line of premium services, such as a case-management concierge service that would more hands-on advice, he says.

Medivizor hasn’t accomplished any of this as of yet. Rather, it’s only done beta testing of the service on a small basis and formed partnerships with patient organizations like the Colon Cancer Coalition and Chris 4 Life to help promote it. But Givoly still says that the company believes that it can be successful enough to become cash flow positive with these types of revenue streams in about 12 months. Its biggest roadblock, he says, is making the people who need the service aware that it exists. The company is also working to add other conditions such as multiple sclerosis to its menu as it begins offering the service.

“We feel that there’s a lot of people that can benefit from this,” he says. “Every day we make these connections that can save peoples’ lives, or improve their quality of life. And people are really thanking us all the time for doing that.”

Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail him at bfidler@xconomy.com Follow @benthefidler

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.